Imugene (IMU.AX) Aktie Kurs

Imugene Ltd is primarily active in the biotechnology industry.

The main competitors of Imugene Ltd in the market include major biopharmaceutical companies such as Merck & Co., Inc., Novartis AG, Bristol-Myers Squibb Company, and Pfizer Inc. These companies also specialize in developing innovative treatments and therapies for various diseases and disorders.

Imugene Ltd is a biopharmaceutical company dedicated to developing innovative immunotherapies to treat cancer. Founded in 1983, Imugene has a rich history in the field of oncology research and drug development. The company focuses on creating targeted immunotherapies that harness the power of the immune system to fight cancer cells. Imugene is committed to addressing unmet medical needs and improving patient outcomes. With a strong team of experienced scientists and a robust pipeline of promising drug candidates, Imugene aims to revolutionize cancer treatment and provide hope to patients worldwide. Imugene Ltd continues to strive towards its mission of developing much-needed advancements in the oncology field.

Imugene Ltd has achieved several significant milestones. The company successfully completed a Phase 1b study for its HER-Vaxx cancer immunotherapy in gastric cancer patients. Imugene also received approval from the US FDA to initiate its Phase 2 study for HER-Vaxx in gastric cancer. Additionally, Imugene has entered collaborations with renowned academic institutions, including City of Hope, to conduct preclinical and clinical trials for various cancer treatments. The company has made considerable progress in advancing its innovative immunotherapy pipeline, which shows great potential in the field of oncology. Imugene Ltd continues to strive for excellence and breakthroughs in cancer treatments.

Imugene Ltd is primarily present in Australia, United States, and Europe.

Imugene Ltd represents values of innovation, collaboration, and patient-centricity. With a strong corporate philosophy, the company aims to revolutionize cancer treatment through its cutting-edge immunotherapy technologies. Imugene prioritizes scientific expertise and fosters strategic partnerships to advance its pipeline of novel and targeted therapies. The company's commitment to improving treatment outcomes for patients is evidenced by its emphasis on clinical development, rigorous research, and commercialization of innovative products. Imugene's inclusive approach promotes open communication and collaboration among researchers, clinicians, and industry experts, reinforcing its dedication to making a significant impact in the fight against cancer.

5 analytikere vurderer i øjeblikket Imugene-aktien: 4 anbefaler køb, 1 hold og 0 salg.

Imugene Analytikerens Kursmål 2026

Omregnet til den aktuelle valutakurs handles Imugene-aktien til 0,02 EUR (0,04 AUD).

Imugene-aktien (IMU.AX) er noteret på 2 børser, herunder: ASX (IMU.AX).

Imugene Ltd is an Australian biopharmaceutical company that focuses on researching, developing, and marketing innovative therapeutic solutions for the treatment of cancer and infectious diseases. The company uses a unique technology platform to responsibly develop immuno-oncology products. Imugene is headquartered in Sydney, Australia, and has additional offices in the USA and Europe. The four main business areas of Imugene are: 1) Immuno-Oncology Products, 2) Immunomodulating Solutions in Cancer, 3) Infectious Diseases, and 4) Partner Programs. Imugene aims to expand its portfolio of immunotherapeutics through new product development and collaborations. It strives to revolutionize the treatment of cancer and infectious diseases with its unique technology platform and comprehensive portfolio of immunotherapeutics. Imugene is well-positioned to become a leading player in the biopharmaceutical industry with its presence in Australia, the USA, and Europe.

Omsætningen kan for øjeblikket ikke beregnes for Imugene.

-overskuddet for Imugene er -105,34 Mio. AUD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.

Pris-til-indtjening-forholdet (P/E) for Imugene er i øjeblikket -0,13. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Imugene-aktien.

P/S-forholdet kan ikke beregnes for Imugene i øjeblikket.

AlleAktien-kvalitetsscore for Imugene er 4/10.

ISIN for Imugene er AU000000IMU9. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.

WKN for Imugene er 891460. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.

Tickeren for Imugene er IMU.AX. Tickersymbolet bruges til at handle Imugene-aktier på børsen.